Market Overview:
The global encephalitis vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as rising incidence of encephalitis, increasing awareness about encephalitis vaccines, and technological advancements in the field of vaccine development. The global encephalitis vaccine market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into Nakayama encephalitis vaccine, Beijing encephalitis vaccine P-3 virus strain live attenuated Japanese B Encephalitis (JE) Vaccine SA 14-14-2), and others. On the basis of application, the market is divided into child vaccination and adult vaccination. Geographically, it has been analyzed across North America (U.S., Canada), Latin America (Mexico Brazil), Europe (Germany France U.K.), Asia Pacific (China Japan India South Korea Australia Singapore Malaysia Indonesia Thailand Vietnam Philippines Pakistan Sri Lanka Bangladesh Maldives), Middle East & Africa(South Africa Saudi Arabia UAE Qatar Kuwait Oman Bahrain Jordan).
Product Definition:
Encephalitis vaccine is a vaccine that helps protect against encephalitis, a serious infection of the brain. It is usually given as part of a combination vaccine that also protects against other diseases, such as diphtheria, tetanus, and pertussis (whooping cough). Encephalitis can cause permanent damage to the brain and even death. The encephalitis vaccine is very important for people who are at risk for this disease, such as children and adults who travel to countries where there is an increased risk for encephalitis.
Nakayama:
Nakayama is a new adjuvant developed by GlaxoSmithKline for the Japanese encephalitis vaccine. Nakayama consists of protein from the yeast, Saccharomyces cerevisiae, which helps in stimulating an immune response to fight against viruses. The vaccine was licensed in Japan on December 1st, 2001 and was approved for sale and use in other countries on January 1st, 2002.
Beijing:
Beijing is the capital of China and it's usage in encephalitis vaccine market is as follows: In 1798, Lord Elgin, the then British ambassador to China presented a smallpox vaccine to the Chinese government. This was followed by another vaccination campaign in 1807 that resulted in about 60% of all Chinese citizens being vaccinated against smallpox. These were some of the first vaccines ever created and distributed free across an entire population with no strings attached.
Application Insights:
Based on the application, the global encephalitis vaccine market is segmented into child and adult. The child segment held a larger share in 2017 owing to higher incidence of encephalitis in children as compared to adults. According to WHO, around 90% of cases occur in children below 14 years of age. In addition, high attack rate among young adults also contributes towards a large share for this segment.
The adult application is expected to grow at fastest rate during forecast period due to rising incidences of viral infections such as West Nile virus and Japanese Encephalitis (JE) that predominantly affect adults above 40 years old population group across the globe. For instance, according these statistics published by CDC; over 30 million people were affected by JE across America from 2016-2017 season while over 1 million were diagnosed with JEV during same time period according data provided by state health departments throughout U.S.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and research-based institutes involved in developing vaccines for encephalitis is one of the major factors contributing to its largest share. In addition, increasing awareness about vaccination programs among people is also expected to drive growth during the forecast period.
Asia Pacific region is anticipated to witness significant growth over the forecast period owing to rising incidence rates of this disease coupled with growing target population base especially in India and China. Furthermore, increasing government initiatives such as “One Child†policy implemented by Chinese Government are expected boost vaccine penetration rate over this region during future years which will further enhance market size estimates for Encephalitis Vaccine Market Asia Pacific (EVAP).
Growth Factors:
- Increasing incidence of encephalitis across the globe
- Growing awareness about encephalitis and its prevention
- Rising demand for effective and safe vaccines against encephalitis
- Technological advancements in vaccine development process
- increasing funding for research on new encephalitis vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Encephalitis Vaccine Market Research Report
By Type
Nakayama, Beijing, P-3, SA 14-14-2
By Application
Child, Adult
By Companies
Liaoning Chengda, Wuhan Institute of Biological, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, Biken
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Encephalitis Vaccine Market Report Segments:
The global Encephalitis Vaccine market is segmented on the basis of:
Types
Nakayama, Beijing, P-3, SA 14-14-2
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Child, Adult
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Liaoning Chengda
- Wuhan Institute of Biological
- Valneva
- Tiantan Biological Products
- Sanofi Pasteur
- Chengdu Institute of Biological Products
- GlaxoSmithKline
- Lanzhou Institute of Biological Products
- Zhejiang Tianyuan Bio-Pharmaceutical
- Biken
Highlights of The Encephalitis Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nakayama
- Beijing
- P-3
- SA 14-14-2
- By Application:
- Child
- Adult
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Encephalitis Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Encephalitis vaccine is a vaccine that helps protect people from a serious brain infection. It is made from pieces of the virus that cause encephalitis (a type of brain infection). Encephalitis vaccines help prevent infections by the viruses that cause encephalitis.
Some of the key players operating in the encephalitis vaccine market are Liaoning Chengda, Wuhan Institute of Biological, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, Biken.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Encephalitis Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Encephalitis Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Encephalitis Vaccine Market - Supply Chain
4.5. Global Encephalitis Vaccine Market Forecast
4.5.1. Encephalitis Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Encephalitis Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Encephalitis Vaccine Market Absolute $ Opportunity
5. Global Encephalitis Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Encephalitis Vaccine Market Size and Volume Forecast by Type
5.3.1. Nakayama
5.3.2. Beijing
5.3.3. P-3
5.3.4. SA 14-14-2
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Encephalitis Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Encephalitis Vaccine Market Size and Volume Forecast by Application
6.3.1. Child
6.3.2. Adult
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Encephalitis Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Encephalitis Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Encephalitis Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Encephalitis Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Encephalitis Vaccine Demand Share Forecast, 2019-2029
9. North America Encephalitis Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Encephalitis Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Encephalitis Vaccine Market Size and Volume Forecast by Application
9.4.1. Child
9.4.2. Adult
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Encephalitis Vaccine Market Size and Volume Forecast by Type
9.7.1. Nakayama
9.7.2. Beijing
9.7.3. P-3
9.7.4. SA 14-14-2
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Encephalitis Vaccine Demand Share Forecast, 2019-2029
10. Latin America Encephalitis Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Encephalitis Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Encephalitis Vaccine Market Size and Volume Forecast by Application
10.4.1. Child
10.4.2. Adult
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Encephalitis Vaccine Market Size and Volume Forecast by Type
10.7.1. Nakayama
10.7.2. Beijing
10.7.3. P-3
10.7.4. SA 14-14-2
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Encephalitis Vaccine Demand Share Forecast, 2019-2029
11. Europe Encephalitis Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Encephalitis Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Encephalitis Vaccine Market Size and Volume Forecast by Application
11.4.1. Child
11.4.2. Adult
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Encephalitis Vaccine Market Size and Volume Forecast by Type
11.7.1. Nakayama
11.7.2. Beijing
11.7.3. P-3
11.7.4. SA 14-14-2
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By ountry
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Encephalitis Vaccine Demand Share, 2019-2029
12. Asia Pacific Encephalitis Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Encephalitis Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Encephalitis Vaccine Market Size and Volume Forecast by Application
12.4.1. Child
12.4.2. Adult
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Encephalitis Vaccine Market Size and Volume Forecast by Type
12.7.1. Nakayama
12.7.2. Beijing
12.7.3. P-3
12.7.4. SA 14-14-2
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Encephalitis Vaccine Demand Share, 2019-2029
13. Middle East & Africa Encephalitis Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Encephalitis Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Encephalitis Vaccine Market Size and Volume Forecast by Application
13.4.1. Child
13.4.2. Adult
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Encephalitis Vaccine Market Size and Volume Forecast by Type
13.7.1. Nakayama
13.7.2. Beijing
13.7.3. P-3
13.7.4. SA 14-14-2
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Encephalitis Vaccine Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Encephalitis Vaccine Market: Market Share Analysis
14.2. Encephalitis Vaccine Distributors and Customers
14.3. Encephalitis Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Liaoning Chengda
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Wuhan Institute of Biological
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Valneva
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Tiantan Biological Products
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi Pasteur
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Chengdu Institute of Biological Products
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlaxoSmithKline
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Lanzhou Institute of Biological Products
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Zhejiang Tianyuan Bio-Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Biken
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
